Skip to main content

Table 2 Frequency distribution of the studied patients according to rheumatoid arthritis characteristics

From: Evaluation of sexual dysfunction and its predictive factors in female and male patients with rheumatoid arthritis

 

Female (n = 248 )

Males (n =94)

Test of sig.

p

Disease duration

  Mean ± SD.

7.5 ± 5.3

10 ± 6.7

U = 8828.0*

0.001*

  Median (min.–max.)

6 (2–23 )

7 (2.5–28 )

DAS Activity

  Remission (<2.6)

106 (42.7)

28 (29.8)

χ2 = 85.379*

<0.001*

  Mild (2.6–3.2)

20 (8.1)

24 (25.5)

  Moderate (3.2–5.1)

44 (17.7)

30 (31.9)

  Severe activity (>5.1)

78 (31.5)

12 (12.8)

  Mean ± SD.

5.5 ± 8.2

4.1 ± 1.9

U = 11560.0

0.906

  Median (min.–max.)

2 (1–34 )

3.1 (0.5–7 )

HADs A

  Normal (0–7)

214 (86.3)

78 (83.0)

χ2 = 7.705

0.071

  Borderline (8–10)

18 (7.3)

4 (4.3)

  Abnormal (11–21(

16 (6.5)

12 (12.7)

  Mean ± SD.

4.1 ± 3.2

3.3 ± 2.1

U = 10496.0

0.148

  Median (min.–max.)

3 (0–15)

3 (0–9)

HADs D

  Normal (0–7)

136 (54.8)

64 (68.1)

χ2 = 6.305*

0.043*

  Borderline (8–10)

52 (21.0)

10 (10.6)

  Abnormal (11–21)

60 (24.2)

20 (21.3)

  Mean ± SD.

8.9 ± 5.8

7.1 ± 4.9

U = 11063.0*

0.026*

  Median (min.–max.)

6 (1–21)

7 (0–19)

HAQ score

  No difficulty (0)

68 (27.4)

36 (38.3)

χ2 = 8.652*

0.034*

  Some difficulty (1)

68 (27.4)

18 (19.1)

  Much difficulty (2)

86 (34.7)

24 (25.5)

  Unable to do (3)

26 (10.5)

16 (17 )

  Mean ± SD.

1.3 ± 1

1.2 ± 1.1

U = 11116.0

0.491

  Median (min.–max.)

1 (0–3 )

1 (0–3 )

VAS score

  No pain (0–4)

18 (7.2)

8 (8.5)

χ2 = 16.420*

< 0.001*

  Mild (5–44)

110 (44.5)

50 (53.2)

  Moderate (45–74)

94 (37.8)

16 (17.0)

  Severe (75–100)

26 (10.5)

20 (21.3)

  Mean ± SD.

44.4 ± 23.6

36.7 ± 25.9

U = 10464.0*

0.043*

  Median (min.–max.)

40 (0–95)

35 (0–90)

Joint deformity

  No deformity

144 (58.1)

52 (55.3)

χ2 = 1.307

0.253

  Deformity

104(41.9)

42 (44.7)

Number of drugs

  Monotherapy

60 (24.2)

20 (21.3)

χ2 = 3.535

0.316

  Ditherapy

94 (37.9)

30 (31.9)

  Triple therapy

52 (21)

20 (21.3)

  Biological therapy

42 (16.9)

24 (25.5)

  1. χ2 chi-square test, U Mann-Whitney test, P p value for comparing between the studied groups. *Statistically significant at P ≤ 0.05